FIGARO-DKD is the first contemporary Phase III CV outcomes trial with the majority of patients with earlier stage CKD (defined as estimated glomerular filtration rate [eGFR] ≥60 mL/min/1.73 m2) with albuminuria to show CV benefit in patients with CKD associated with T2D.
Kerendia provides dual cardiorenal risk reduction in adults with CKD associated with T2D.
Kerendia was approved in the US by the FDA in July 2021 to reduce the risk of sustained eGFR decline, end-stage kidney disease, CV death, non-fatal myocardial infarction and hospitalization for heart failure in adult patients with CKD associated with T2D, based on the results of the FIDELIO-DKD pivotal trial.
FIGARO-DKD showed that Kerendia significantly reduced the risk of the primary composite endpoint of time to first occurrence of CV death, non-fatal MI, non-fatal stroke or hospitalization for heart failure by 13% (relative risk reduction, HR 0.87 [95% CI, 0.76-0.98; P=0.026]) over a median duration of follow-up of 3.4 years when added to maximum tolerated dose of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in adults with CKD associated with T2D.
In FIGARO-DKD, the treatment effect was primarily driven by a 29% risk reduction in hospitalization for HF (HR 0.71 [95% CI, 0.56-0.90]).
A 10% risk reduction in CV death (HR 0.90 [95% CI, 0.74-1.09]) also contributed to the treatment effect.
With the addition of these study findings, the US label now includes data from Kerendia's comprehensive Phase III clinical trial program investigating kidney and CV outcomes in more than 13,000 patients with CKD associated with T2D.
Kerendia works by blocking overactivation of the mineralocorticoid receptor in the kidney, heart and blood vessels, which is thought to lead to inflammation and fibrosis.
Mineralocorticoid receptor overactivation is an important factor to consider when evaluating the risk of CV events and CKD progression in patients with CKD associated with T2D.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes